We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Essex Woodlands leads $40.4mm Series C round for Catalyst
19 Mar 2013
Executive Summary
First-time investor Essex Woodlands led the $40.4mm Series C financing for Catalyst Biosciences (redesigns proteases--called Alterases--that target disease-causing proteins). Returning backers Burrill & Co., HealthCare Ventures, Johnson & Johnson Development Corp., Morgenthaler Ventures, Novartis BioVentures, and Sofinnova Ventures also participated. A managing director from Essex joined the company's board. Catalyst says it will now have enough money to support its activities for the next few years, including moving its CB813 Factor VIIa treatment for hemophilia (currently at the preclinical stage) through Phase I/II proof-of-concept studies.
Deal Industry
Pharmaceuticals
Biotechnology
Large Molecule
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?